Navigation Links
Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain
Date:6/30/2011

CHADDS FORD, Pa., June 30, 2011 /PRNewswire/ -- Endo Pharmaceuticals (Nasdaq: ENDP) announced today topline results from a phase 2 study comparing the novel investigational drug axomadol against placebo in the treatment of patients with moderate to severe chronic low back pain. The results indicate that axomadol did not meet predetermined study end points. The company is currently completing additional analyses of the data and evaluating the path forward for the program.

The study was a randomized, double blind, two-arm, placebo-controlled, parallel group design and included 236 patients with moderate to severe chronic low back pain. Axomadol was orally administered at doses ranging from 100 mg/day to 300 mg/day over a four-week period with a 12-week maintenance phase. The primary outcome measure was change in average pain intensity using a Numerical Rating Scale (NRS) from baseline to final week of treatment for all patients receiving at least one dose of study drug.  

Endo licensed exclusive rights to develop and market axomadol in the United States and Canada from Grunenthal in February 2009.

About Endo Pharmaceuticals

Endo Pharmaceuticals is a U.S.-based, specialty healthcare solutions company, focused on high-value branded products and specialty generics. Endo is redefining its position in the healthcare marketplace by anticipating and embracing the evolution of health decisions based on the need for high-quality and cost-effective care. We aim to be the premier partner to healthcare professionals and payment providers, delivering an innovative suite of complementary diagnostics, drugs, devices and clinical data to meet the needs of patients in areas such as pain, urology, oncology and endocrinology. For more information about Endo Pharmaceuticals, and its wholly owned subsidiaries American Medical Systems, Inc., HealthTronics, Inc. and
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytrens Contracture
2. Valeant Pharmaceuticals Announces License Agreement With Meda for North American Rights for Elidel® and Xerese™
3. Cell Therapeutics, Inc. Announces Institutional Investors Purchase $30 Million of Preferred Stock and Warrants
4. diaDexus Preannounces Strong Second Quarter Revenues
5. Par Pharmaceutical Companies Announces a Restructuring of Its Branded Division, Strativa Pharmaceuticals, to Maximize Profitability
6. UBM Canon Announces New Japanese-Language Website for Japan Medical Design & Manufacturing Technology: www.jmdmt.com
7. Micell Technologies Announces Reduced Clinical Trial Sample Size for MiStent® Drug-Eluting Coronary Stent Based on Early Clinical Data
8. Suneva Medical Announces Canadian Approval of Bellafill™
9. McNeil Consumer Healthcare Announces Voluntary Recall of One Product Lot of TYLENOL® Extra Strength Caplets 225 Count Distributed in the U.S.
10. Lutonix Announces Achievement of Significant Milestones and Additions to Executive Leadership Team
11. Novelos Therapeutics Announces Dismissal of Putative Federal Securities Class Action Lawsuit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Germany und ... , Ziel der Zusammenarbeit ... Basis genomischer Daten aus Plasmaproben zur Steuerung von ... eingesetzt werden kann  Neuer Bluttest basiert ... Kit und soll auf Rotor-Gene Q, einer Automationsplattform ...
(Date:7/27/2014)... July 27, 2014 /PRNewswire-iReach/ -- This is ... Global and Chinese Vardenafil (CAS 224785-90-4) industry. ... of Vardenafil (CAS 224785-90-4) including its classification, ... explores global and China,s top manufacturers of ... capacity, production value, cost, gross margin and ...
(Date:7/25/2014)...  Depomed, Inc. (NASDAQ: DEPO ) today ... 2014 financial results after the market closes on Wednesday, August ... beginning at 4:30 pm EDT, 1:30 pm PDT to discuss its ... dialing 877-317-6789 ( United States ) or ... via a live webcast on the investor relations section ...
Breaking Medicine Technology:QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 3QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 4QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 5QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 6QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 7Global and Chinese Vardenafil Industry (CAS 224785-90-4) 2019 Forecasts 2Global and Chinese Vardenafil Industry (CAS 224785-90-4) 2019 Forecasts 3Global and Chinese Vardenafil Industry (CAS 224785-90-4) 2019 Forecasts 4Depomed To Report Second Quarter Fiscal Year 2014 Financial Results On Wednesday, August 6, 2014 2
(Date:7/28/2014)... one of the UK,s most common respiratory diseases has ... disease (COPD) is the name for a collection of ... to the lungs. Often linked to smoking, it ... admissions in the UK, with a high proportion of ... , A team of researchers, led by ...
(Date:7/28/2014)... Modesto, CA (PRWEB) July 28, 2014 At ... an uncomfortable situation where they’re forced to contact the authorities. ... little more difficult than it initially seems. , Not every ... a vehicle get stolen, a person get mugged, or a ... little less obvious, leading onlookers to be more passive than ...
(Date:7/28/2014)... Researchers from Boston University School of Medicine (BUSM) report ... the risk of developing Alzheimer,s disease (AD). The discovery ... drug treatment options that target PLXNA4 specifically. These findings ... AD is the most frequent age-related dementia affecting 5.4 ... and older, and more than 40 percent of people ...
(Date:7/28/2014)... 28, 2014 Qualis Health, one ... management organizations, has published a complimentary, online toolkit ... engaging patients and families in infection control. ... hospitals, the toolkit provides a step-by-step roadmap for ... and their families early in a hospital stay. ...
(Date:7/28/2014)... The North America Carotenoids & Antioxidants Market ... North America with analysis and forecast of revenue. This market ... to $812.7 million by 2018, at a CAGR of 7.1% ... the North America Carotenoids & Antioxidants Market report to get ... a glimpse of the segmentation in the market, and is ...
Breaking Medicine News(10 mins):Health News:New research to tackle treatment for lung disease 2Health News:New research to tackle treatment for lung disease 3Health News:Take Action To Protect Your Fellow Citizens 2Health News:Take Action To Protect Your Fellow Citizens 3Health News:Researchers identify potential biomarker for AD 2Health News:Patient Engagement in Hospital Infection Control: Online Toolkit Provides a New Solution 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 4
... Scientists at Warwick Medical School have uncovered the molecular ... ,health checkpoint, with cells that carry unequal numbers of ... , Studying simple yeast cells, scientists now understand the ... the correct number of chromosomes. , Most ...
... State University will lead a four-year, $5 million expanded ... discover proteins, or biomarkers, to help predict cardiovascular disease ... type 2 diabetes. Nearly 26 million Americans have ... U.S. The disease is a major cause of heart ...
... , TUESDAY, Nov. 1 (HealthDay News) -- Multiple sclerosis ... aim at the abnormal behavior of a specific type of ... the cells in question -- known as "B cells" -- ... and disabling nervous system disease, commonly called MS. The ...
... high school students are considered overweight, and while a myriad ... parents can do to help curb these rates, very little ... lose weight. Research led by public health doctoral candidate ... Philadelphia report wanting to lose weight, their actions are more ...
... an eight hour shift leads to substantial cost savings and energy ... Journal of the American College of Radiology . ... the use of computers and scanning equipment. "We should ... this equipment and look for ways to reduce it, both as ...
... NYU Langone Medical Center identified for the first time that ... outer and inner layers of the brain, called "blurring", may ... development of new therapies for degenerative brain conditions, such as ... issue of the Journal of Neuroscience . ...
Cached Medicine News:Health News:Warwick scientists discover how daughter cells receive the same number of chromosomes 2Health News:ASU leads $5 million NIH-sponsored research initiative to advance diabetes care and treatment 2Health News:ASU leads $5 million NIH-sponsored research initiative to advance diabetes care and treatment 3Health News:New Multiple Sclerosis Therapy Promising in Early Trial 2Health News:New Multiple Sclerosis Therapy Promising in Early Trial 3Health News:Study finds overweight teens want to lose weight, going about it the wrong way 2Health News:Neurologists identify potential biomarker of cognitive decline for earlier diagnosis of disease 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: